# An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals

> **NCT00489385** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 41 (actual)

## Conditions studied

- HIV Infections
- HCV

## Interventions

- **DRUG:** Albinterferon
- **DRUG:** Ribavirin
- **DRUG:** Albuferon

## Key facts

- **NCT ID:** NCT00489385
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-18
- **Primary completion:** 2011-03-15
- **Final completion:** 2011-03-15
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489385, "An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00489385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*